News
Romosozumab, used in osteoporosis treatment, may offer dual benefits by also reducing the risk for osteoarthritis, notably knee osteoarthritis.
SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.
Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release. The agreement adds Zilretta, an injectable osteoarthritis treatment, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results